An efficient constitutive expression system for Anti-CEACAM5 nanobody production in the yeast Pichia pastoris.


Journal

Protein expression and purification
ISSN: 1096-0279
Titre abrégé: Protein Expr Purif
Pays: United States
ID NLM: 9101496

Informations de publication

Date de publication:
03 2019
Historique:
received: 10 10 2018
accepted: 05 11 2018
pubmed: 12 11 2018
medline: 13 3 2020
entrez: 12 11 2018
Statut: ppublish

Résumé

Nanobodies offer multiple advantages over conventional antibodies in terms of size, stability, solubility, immunogenicity, and production costs, with improved tumor uptake and blood clearance. Additionally, the recombinant expression of nanobodies is robust in various expression systems, such as Escherichia coli, Saccharomyces cerevisiae and Pichia pastoris. P. pastoris is the most widely used microorganism for nanobody production, but all or almost all expression vectors developed for this system are based on the regulated promoter of the alcohol oxidase 1 gene (AOX1) that requires methanol for full induction. In this study, a constitutive anti-CEACAM5 nanobody expression system was constructed under the control of a glyceraldehyde-3-phosphate dehydrogenase promoter (GAP) promoter. The effects of different carbon sources and pH on nanobody expression were evaluated in shaking flask cultures. After 96 h of constitutive expression in shaking flask, a yield of 51.71 mg/L was obtained. In addition, this constitutive expression system produced nanobodies at equivalent yield and affinity to that produced by methanol-induced expression. The results of this study indicated that the use of a constitutive expression system is a promising alternative for the production of nanobodies applied for cancer diagnosis and therapy.

Identifiants

pubmed: 30414968
pii: S1046-5928(18)30525-4
doi: 10.1016/j.pep.2018.11.001
pii:
doi:

Substances chimiques

CEACAM5 protein, human 0
Carcinoembryonic Antigen 0
GPI-Linked Proteins 0
Recombinant Proteins 0
Single-Domain Antibodies 0
Glyceraldehyde-3-Phosphate Dehydrogenases EC 1.2.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-47

Informations de copyright

Copyright © 2018 Elsevier Inc. All rights reserved.

Auteurs

Quan Chen (Q)

CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, China.

Yuhang Zhou (Y)

Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, China.

Jianli Yu (J)

Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, China.

Wenshuai Liu (W)

CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, China.

Fei Li (F)

Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, China.

Mo Xian (M)

CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, China.

Rui Nian (R)

CAS Key Laboratory of Biobased Materials, Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, No. 189 Songling Road, Qingdao, 266101, China. Electronic address: nianrui@qibebt.ac.cn.

Haipeng Song (H)

Shenzhen Innova Nanobodi Co., Ltd., No. 7018 Caitian Road, Shenzhen, 518000, China. Electronic address: patrick.song@nanobodi.com.

Dongxiao Feng (D)

School of Pharmaceutical Sciences, Binzhou Medical University, No. 346 Guanhai Road, Yantai, 264003, China. Electronic address: fengdx@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH